On Tuesday, Pyxis Oncology Inc (NASDAQ: PYXS) was -6.00% drop from the session before settling in for the closing price of $2.00. A 52-week range for PYXS has been $1.59 – $6.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 41.24%. With a float of $41.12 million, this company’s outstanding shares have now reached $59.45 million.
In an organization with 50 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.98%, operating margin of -343.24%, and the pretax margin is -293.15%.
Pyxis Oncology Inc (PYXS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pyxis Oncology Inc stocks. The insider ownership of Pyxis Oncology Inc is 30.85%, while institutional ownership is 51.89%. The most recent insider transaction that took place on Nov 26 ’24, was worth 174,364. In this transaction CFO & COO of this company bought 88,850 shares at a rate of $1.96, taking the stock ownership to the 1,199,143 shares.
Pyxis Oncology Inc (PYXS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.33 earnings per share (EPS) during the time that was better than consensus figure (set at -0.47) by 0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.60% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
You can see what Pyxis Oncology Inc (PYXS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.21 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Let’s dig in a bit further. During the last 5-days, its volume was 2.14 million. That was better than the volume of 0.77 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 7.97%. Additionally, its Average True Range was 0.33.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 3.31%, which indicates a significant decrease from 3.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 245.03% in the past 14 days, which was higher than the 119.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.43, while its 200-day Moving Average is $3.95. However, in the short run, Pyxis Oncology Inc’s stock first resistance to watch stands at $1.98. Second resistance stands at $2.08. The third major resistance level sits at $2.16. If the price goes on to break the first support level at $1.80, it is likely to go to the next support level at $1.72. The third support level lies at $1.62 if the price breaches the second support level.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
There are 59,466K outstanding shares of the company, which has a market capitalization of 111.79 million. As of now, sales total 0 K while income totals -73,790 K. Its latest quarter income was 0 K while its last quarter net income were -17,300 K.
